TGFB1 and chronic myelogenous leukemia, BCR-ABL1 positive: The TGF-β signaling pathway appears to play an important role in the recovery of immune surveillance in CML; thus, the elevation of TGFB in patients with optimal responses at 12 months of treatment may be explained by this.